{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:56:45Z","timestamp":1782129405211,"version":"3.54.5"},"publisher-location":"Cham","reference-count":23,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030511395","type":"print"},{"value":"9783030511401","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-51140-1_8","type":"book-chapter","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:30:34Z","timestamp":1610497834000},"page":"113-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Frontotemporal Dementia Prevention Initiative: Linking Together Genetic Frontotemporal Dementia Cohort Studies"],"prefix":"10.1007","author":[{"given":"Jonathan D.","family":"Rohrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"8_CR1","unstructured":"Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM et al (2017) DIAN-TU pharma consortium for the dominantly inherited Alzheimer network. The DIAN-TU Next Generation Alzheimer\u2019s prevention trial: Adaptive design and disease progression model. Alzheimers Dement 13(1):8\u201319"},{"key":"8_CR2","doi-asserted-by":"crossref","unstructured":"Boxer AL, Gold M, Feldman H, Boeve BF, Dickinson SL, Fillit H et al (2020) New directions in clinical trials for frontotemporal lobar degeneration: methods and outcome measures. Alzheimers Dement 16(1):131\u2013143","DOI":"10.1016\/j.jalz.2019.06.4956"},{"key":"8_CR3","doi-asserted-by":"crossref","unstructured":"Chen Q, Boeve BF, Senjem M, Tosakulwong N, Lesnick T, Brushaber D et al (2020) Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study Neurobiol Aging 88:42\u201350","DOI":"10.1016\/j.neurobiolaging.2019.12.004"},{"key":"8_CR4","doi-asserted-by":"crossref","unstructured":"Chen Q, Boeve BF, Senjem M, Tosakulwong N, Lesnick TG, Brushaber D et al (2019) Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimers Dement (N Y) 5:338\u2013346","DOI":"10.1016\/j.trci.2019.05.010"},{"key":"8_CR5","doi-asserted-by":"crossref","unstructured":"Coyle-Gilchrist IT, Dick KM, Patterson K, V\u00e1zquez Rodr\u00edquez P, Wehmann E, Wilcox A et al (2016) Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86(18):1736\u20131743","DOI":"10.1212\/WNL.0000000000002638"},{"key":"8_CR6","unstructured":"Galimberti D, Fumagalli GG, Fenoglio C, Cioffi SMG, Arighi A, Serpente M et al (2018) Genetic FTD Initiative (GENFI) Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiol Aging 62:245.e9\u2013245.e12"},{"issue":"8","key":"8_CR7","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00415-019-09363-4","volume":"266","author":"CV Greaves","year":"2019","unstructured":"Greaves CV, Rohrer JD (2019) An update on genetic frontotemporal dementia. J Neurol 266(8):2075\u20132086","journal-title":"J Neurol"},{"key":"8_CR8","doi-asserted-by":"crossref","unstructured":"Heller C, Foiani MS, Moore K, Convery R, Bocchetta M, Neason M et al (2020 Mar) Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry 91(3):263\u2013270","DOI":"10.1136\/jnnp-2019-321954"},{"key":"8_CR9","doi-asserted-by":"crossref","unstructured":"Jiskoot LC, Bocchetta M, Nicholas JM, Cash DM, Thomas D, Modat M et al (2018) Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: a cross-sectional diffusion tensor imaging study. Ann Clin Transl Neurol 5(9):1025\u20131036","DOI":"10.1002\/acn3.601"},{"key":"8_CR10","doi-asserted-by":"crossref","unstructured":"Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L et al (2016) Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3(8):623\u2013636","DOI":"10.1002\/acn3.325"},{"key":"8_CR11","doi-asserted-by":"crossref","unstructured":"Meeter LHH, Gendron TF, Sias AC, Jiskoot LC, Russo SP, Donker Kaat L et al (2018) Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol 5(5):583\u2013597","DOI":"10.1002\/acn3.559"},{"key":"8_CR12","doi-asserted-by":"crossref","unstructured":"Miyagawa T, Brushaber D, Syrjanen J, Kremers W, Fields J, Forsberg LK et al (2020) Use of the CDR\u00ae plus NACC FTLD in mild FTLD: data from the ARTFL\/LEFFTDS consortium. Alzheimers Dement 16(1):79\u201390","DOI":"10.1016\/j.jalz.2019.05.013"},{"key":"8_CR13","doi-asserted-by":"crossref","unstructured":"Moore KM, Nicholas J, Grossman M, McMillan CT, Irwin DJ, Massimo L et al (2020) Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol 19(2):145\u2013156","DOI":"10.1016\/S1474-4422(19)30394-1"},{"key":"8_CR14","doi-asserted-by":"crossref","unstructured":"Olney NT, Ong E, Goh SM, Bajorek L, Dever R, Staffaroni AM et al (2020) Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimers Dement 16(1):49\u201359","DOI":"10.1016\/j.jalz.2019.08.196"},{"issue":"2","key":"8_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3109\/09540261.2013.776523","volume":"25","author":"CU Onyike","year":"2013","unstructured":"Onyike CU, Diehl-Schmid J (2013) The epidemiology of frontotemporal dementia. Int Rev Psychiatry 25(2):130\u2013137","journal-title":"Int Rev Psychiatry"},{"key":"8_CR16","doi-asserted-by":"crossref","unstructured":"Quintana M, Shrader J, Slota C, Joe G, McKew JC, Fitzgerald M et al (2019) Bayesian model of disease progression in GNE myopathy. Stat Med 38(8):1459\u20131474","DOI":"10.1002\/sim.8050"},{"key":"8_CR17","doi-asserted-by":"crossref","unstructured":"Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L et al (2015) Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 14(3):253\u2013262","DOI":"10.1016\/S1474-4422(14)70324-2"},{"issue":"10","key":"8_CR18","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neurol.2013.07.010","volume":"169","author":"JD Rohrer","year":"2013","unstructured":"Rohrer JD, Warren JD, Fox NC, Rossor MN (2013) Presymptomatic studies in genetic frontotemporal dementia. Rev Neurol (Paris) 169(10):820\u2013824","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"8_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/alz.12004","volume":"16","author":"HJ Rosen","year":"2020","unstructured":"Rosen HJ, Boeve BF, Boxer AL (2020) Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: recent findings from ARTFL and LEFFTDS. Alzheimers Dement 16(1):71\u201378","journal-title":"Alzheimers Dement"},{"key":"8_CR20","doi-asserted-by":"crossref","unstructured":"Staffaroni AM, Bajorek L, Casaletto KB, Cobigo Y, Goh SM, Wolf A et al (2020 Jan) Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint. Alzheimers Dement 16(1):11\u201321","DOI":"10.1016\/j.jalz.2019.01.012"},{"key":"8_CR21","doi-asserted-by":"crossref","unstructured":"Sudre CH, Bocchetta M, Heller C, Convery R, Neason M, Moore KM et al (2019) White matter hyperintensities in progranulin-associated frontotemporal dementia: a longitudinal GENFI study. Neuroimage Clin 24:102077","DOI":"10.1016\/j.nicl.2019.102077"},{"key":"8_CR22","doi-asserted-by":"crossref","unstructured":"Tsai RM, Bejanin A, Lesman-Segev O, LaJoie R, Visani A, Bourakova V et al (2019) 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther 11(1):13","DOI":"10.1186\/s13195-019-0470-7"},{"key":"8_CR23","unstructured":"van der Ende EL, Meeter LH, Poos JM, Panman JL, Jiskoot LC, Dopper EGP et al (2019 Dec) Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol 18(12):1103\u20131111"}],"container-title":["Advances in Experimental Medicine and Biology","Frontotemporal Dementias"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-51140-1_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:49:45Z","timestamp":1610498985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-51140-1_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030511395","9783030511401"],"references-count":23,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-51140-1_8","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"13 January 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}